Lung cancer trials in Canada

In Canada 156 Also abroad 2733

156 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Montreal, Ottawa, Québec
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 2/3Not yet taking people in Canada
A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer
Where
London
Age
18 years and over
People
150
Run by
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
See details and how to joinNCT07920549
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Abbotsford British Columbia, Chicoutimi, Vancouver
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Brampton, Montreal, Toronto, Vancouver
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 1/2Taking people
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Where
Edmonton, Toronto
Age
18 years and over
People
675 worldwide
Run by
BlossomHill Therapeutics
See details and how to joinNCT06706076
Phase 2Not yet taking people in Canada
ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)
Where
Toronto
Age
18 years and over
People
60
Run by
University Health Network, Toronto
See details and how to joinNCT06813664
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Toronto, Vancouver
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 2Taking people
Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
Where
Edmonton
Age
18 years and over
People
31
Run by
AHS Cancer Control Alberta
See details and how to joinNCT04952480
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Brampton, Mississauga, Montreal
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 1/2Taking people
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Where
Toronto
Age
18 years and over
People
60 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07227025
Phase 2Taking people
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Where
Toronto
Age
18 years and over
People
68 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07586202
Phase 1Taking people
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Where
Montreal
Age
18 years and over
People
156 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07660055
Phase 3Taking people
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Where
Brampton, Kitchener, London, Newmarket, North Vancouver, Saint John, Windsor
Age
18 years to 90 years
People
507 worldwide
Run by
ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00
Phase 1Taking people
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Where
Toronto
Age
18 years and over
People
77 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07166601
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Brampton, Calgary, Edmonton, Ottawa, Toronto, Vancouver
Age
18 years and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Edmonton, Toronto
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
Phase 1Not yet taking people in Canada
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
Where
Montreal
Age
18 years and over
People
40 worldwide
Run by
Kanvas Biosciences
See details and how to joinNCT07910942
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Edmonton, London, Montreal, Ottawa, Toronto, Vancouver
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 1/2Taking people
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Where
Edmonton
Age
18 years and over
People
450 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00
No phaseTaking people
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Where
Edmonton
Age
18 years and over
People
1,065 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165798
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Brampton, Edmonton, Greenfield Park, Lévis, Montreal
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 3Taking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Kingston, Kitchener, Montreal, Trois-Rivières
Age
18 years and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Greater Sudbury, Hamilton, Montreal, Saint John, Sault Ste. Marie, Sydney
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 3Taking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Chicoutimi, Lévis, London, Montreal, Newmarket, Oshawa, Rimouski, Saskatoon, St. John's, Toronto, Trois-Rivières, Vancouver, Winnipeg
Age
18 years and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Abbotsford British Columbia, Greater Sudbury, Hamilton, Kingston, Montreal, Saint-Jérôme, Saint John, Sault Ste. Marie, Sydney
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00